The bipartisan Medicare Access and CHIP Reauthorization Act (MACRA), signed into law April 2015, eliminated the Sustainable Growth Rate (SGR) and replaced it with the Quality Payment Program (QPP). Clinicians billing Medicare Part B, who meet the eligibility requirements, must participate in the QPP through one of two tracks: the Merit-based Incentive Payment System (MIPS) and Advanced Alternative Payment Models (APMS).
The information below provides an overview of MACRA and its impact on hematology. If your question is not addressed in the FAQs, please visit qpp.cms.gov.
The Centers for Medicare & Medicaid Services (CMS) is implementing multiple flexibilities for the Quality Payment Program (QPP) in response to the 2019 Novel Coronavirus (COVID-19) pandemic public health emergency (PHE). Learn more.
Disclaimer: The information provided here is intended as a general overview and is not comprehensive.
Find out if you are exempt from participating in MIPS, learn how to avoid a negative payment adjustment in 2019, and more
Frequently asked questions about the Medicare Access and CHIP Reauthorization Act
ASH Comment Letters
- ASH Letter on Cost Measures
- ASH Comments on Year 2 of the QPP
- ASH Comments on MACRA Final Rule
- ASH Comments on MACRA Proposed Rule
If you have additional questions related to MACRA, please contact ASH Policy and Practice Manager Leslie Brady at email@example.com or 202-292-0264.